drugset / Trial / NCT00005592
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
23 enrolled
University of Alabama at Birmingham
Biogen · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and ibritumomab tiuxetan in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Timeline
- Start
- 1999-11
- Primary completion
- 2002-03
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | — | Intravenous |